Stock Financial Ratios

SNGX / Soligenix, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price2.02
Volume30,800.00
Market Cap ($M)12.49
Enterprise Value ($M)2.18
Book Value ($M)7.40
Book Value / Share1.35
Price / Book5.55
NCAV ($M)10.11
NCAV / Share-0.76
Price / NCAV3.06
Income Statement (mra) ($M)
Revenue10.45
EBITDA-5.71
Net Income-3.25
Balance Sheet (mrq) ($M)
Cash & Equivalents5.00
Cash / Share0.91
Assets0.00
Liabilities2.71
Quick Ratio3.52
Current Ratio3.52
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.44
Return on Assets (ROA)-21.17
Return on Equity (ROE)-0.44
Identifiers and Descriptors
CUSIP834223307
Central Index Key (CIK)812796
Industry Groups
SIC 2834 - Pharmaceutical Preparations
Other Related CUSIPS
834223117
834223208
Share Statistics
Weighted Average Number Diluted Shares Outstanding Adjustment3,583,587
Common Stock Shares Outstanding5,470,032
Weighted Average Number Of Shares Outstanding Basic3,481,460
Weighted Average Number Of Diluted Shares Outstanding3,583,587
Common Shares Outstanding5,472,532
Scoring Models
Piotroski F-Score4.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Accumulated Depreciation And Depletion Per Share0.00
Cash Per Share0.91
Equity Per Share0.00
Minority Interest Per Share0.00
Inventory Work In Progress Per Share0.00
Additional Paid In Capital Per Share0.00
Long Term Debt Per Share0.00
Treasury Stock Per Share0.00
Accounts Payable Per Share0.00
Debt Per Share0.00
Inventory Per Share0.00
Retained Earnings Per Share0.00
Liabilities And Stock Equity Per Share0.00
Assets Other Non Current Per Share0.00
Intangibles Per Share0.00
Liabilities Per Share0.49
Assets Current Per Share1.05
Goodwill Per Share0.00
Cash And Equivalents Per Share0.91
Property Plant And Equipment Net Per Share0.00
Liabilities Current Per Share0.00
Assets Per Share0.00
Deferred Income Tax Liabilities Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Property Plant And Equipment Gross Per Share0.00
Accounts Receivable Per Share0.00
Property Plant And Equipment Per Share0.00
Inventory Raw Materials Per Share0.00
Assets Other Current Per Share0.00
Inventory Finished Goods Per Share0.00
Liabilities Other Non Current Per Share0.00

Peers - Pharmaceutical Preparations (2834)

Related News Stories

Pluristem - Hidden Treasures And Sudden Catalysts

2018-02-08 seekingalpha
Pluristem (PSTI) is among the cell therapy companies which are racing to completion of a Phase III trial and initiation of two others in the coming months which look to address unmet needs in the medical community. Pluristem primarily utilizes two different placenta-derived cell products, (PDX-PAD and PLX-R18) which look to address a wide collection of therapeutic needs. Their lead product indications are Critical Limb Ischemia [CLI], Hip Fracture recovery and Acute Radiation Syndrome [ARS] (all Phase III) in addition to a Phase II trial in Intermittent Claudication [IC]. (135-3)

BRIEF-Soligenix Identifies Biomarkers For Ricin Toxin Vaccine Testing Under FDA Animal Rule

2017-12-21 reuters
* SOLIGENIX INC - BIOMARKERS FOR RICIN TOXIN VACCINE TESTING BEEN SUCCESSFULLY IDENTIFIED, FACILITATING POTENTIAL APPROVAL UNDER FDA “ANIMAL RULE” (17-1)

BRIEF-‍ACT Capital Management reports 9.9 pct passive stake in Soligenix - SEC filing​

2017-11-07 reuters
* ‍act Capital Management LLLP reports 9.9 percent passive stake in Soligenix Inc as of November 2, 2017 - SEC filing​ Source text: (bit.ly/2yFcZRO) Further company coverage: (Bengaluru Newsroom: +91 806 749 1136) (17-1)

CUSIP: 834223307